目的 基于糖脂代谢病（GLMD）理论和网络药理学方法研究参芪降糖颗粒治疗脂代谢紊乱性疾病的潜在分子机制。方法 借助PubChem Search、Genecards数据库和Swiss target prediction在线工具得到参芪降糖颗粒药效成分治疗脂代谢紊乱性疾病共性靶点；通过STRING数据库构建靶蛋白相互作用（PPI）网络；利用Cytoscape 3.3.0软件构建"疾病-参芪降糖颗粒潜在活性成分-潜在靶点"网络；利用Clue GO插件进行GO分析和KEGG通路富集分析。结果 从参芪降糖颗粒共有115个活性成分与22个与脂代谢紊乱性疾病靶点相互作用。参芪降糖颗粒治疗脂代谢紊乱性疾病参与中等密度脂蛋白颗粒重塑、RNA聚合酶II启动子转录调控糖酵解、白三烯产生和炎症反应等生物过程；并与AGE-RAGE信号通路、NF-κB信号通路、肿瘤坏死因子信号通路、胆汁分泌多条信号通路相关。结论 参芪降糖颗粒治疗脂代谢紊乱性疾病具有多成分-多靶点-多途径的作用特点，其作用机制与糖脂代谢病的基本理论相吻合，能为参芪降糖颗粒临床新应用提供了借鉴和参考。

Objective To analyze the molecular biological mechanism of Shenqi Jiangtang Granules (SJG) in the treatment of lipid metabolism disorder based on network pharmacology and glucolipid metabolic disorders (GLMD) theory. Methods The targets of SJG's active components for treatment of lipid metabolism disorder were screened and predicted by utilizing PubChem Search, Genecards database and Swiss target prediction online tool. The protein-protein interaction (PPI) network was established by using STRING database. Cytoscape 3.3.0 software was adopted to construct a disease-active component-potential target network. Gene ontology (GO) biological process and Kyoto Encyclopedia of Genes and Gnomes (KEGG) pathway enrichment analysis were performed using Clue GO. Results A total of 115 active components of SJG and 22 targets related to lipid metabolism disorder were screened. The active components of SJG regulated intermediate-density lipoprotein particle remodeling, glycolytic process by regulation of transcription from RNA polymerase II promoter and leukotriene production involved in inflammatory response, and participated in AGE-RAGE signaling pathway, NF-κB signaling pathway, TNF signaling pathway and bile secretion. Conclusion This study reflects the characteristics of multi-components, multi-targets, and multi-pathways of SJG, and provides new ideas and clues for new application of SJG, which is consistent with the GLMD theory.

R285.5

国家重点研发计划项目（2018YFC1704200）；国家重点研发计划项目（2018YFC1704205）；国家自然科学基金重点项目（81530102）；国家自然科学基金重点项目（81830113）